SCHEMBL5774786

SCHEMBL5774786

CCOC(=O)c1c(C)noc1-c1c(F)cccc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.56
PKM P14618 2/20 0.56
MAPT P10636 4/20 0.56
TP53 P04637 1/20 0.56
POLB P06746 2/20 0.52
KDM4E B2RXH2 2/20 0.52
HPGD P15428 2/20 0.51
TSHR P16473 2/20 0.51
MAPK1 P28482 1/20 0.51
GAA P10253 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
KMT2A Q03164 4/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MEN1 O00255 2/20 0.47
HTT P42858 1/20 0.47
ESR1 P03372 1/20 0.47
RECQL P46063 1/20 0.46
HSD17B10 Q99714 1/20 0.46
GPBAR1 Q8TDU6 1/20 0.46
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5775889 0.85 FTO (0.49) ALDH1A1MAPTTP53POLBKDM4E
SCHEMBL6641279 0.85 LMNA (0.48) ALDH1A1MAPTTP53POLBKDM4E
SCHEMBL2775568 0.83 MAPT (0.74) ALDH1A1MAPTTP53POLBKDM4E
SCHEMBL30395634 0.81 ALDH1A1 (0.60) ALDH1A1PKMMAPTTP53POLB
SCHEMBL2776763 0.78 MAPT (0.62) ALDH1A1MAPTTP53POLBHPGD
SCHEMBL17055295 0.78 MAPT (0.51) ALDH1A1MAPTTP53KDM4EHPGD
SCHEMBL6801757 0.78 MAPT (0.45) ALDH1A1MAPTTP53POLBKDM4E
SCHEMBL1671664 0.77 LMNA (0.58) ALDH1A1MAPTTP53POLBKDM4E
SCHEMBL19900665 0.77 MAPT (0.60) ALDH1A1MAPTTP53POLBHPGD
SCHEMBL30437437 0.77 MAPT (0.60) ALDH1A1MAPTTP53POLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1224189-B1 CONDENSED DIHYDROQUINOLINONE DERIVATIVES FOR INHIBITING MRP1 LILLY CO ELI (US) 2006-01-25 EP disclosed
EP-1250340-B1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 LILLY CO ELI (US) 2004-11-17 EP disclosed
US-20040176405-A1 Methods and compounds for inhibitting MRP1 KROIN JULIAN (US) 2004-09-09 US disclosed
US-6743794-B2 MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE ELI LILLY AND COMPANY 2004-06-01 US disclosed
US-20040077675-A1 Compounds and methods for inhibiting MRP1 BONJOUKLIAN ROSANNE (US) 2004-04-22 US disclosed
US-6686376-B2 INHIBITING A RESISTANT NEOPLASM, OR A NEOPLASM SUSCEPTIBLE TO RESISTANCE IN A MAMMAL WHICH COMPRISES ADMINISTERING COMPOUND OF INVENTION ELI LILLY AND COMPANY 2004-02-03 US disclosed
US-6670373-B1 Inhibiting resistant neoplasms where the resistance is conferred by multidrug resistance protein; N-3,4,5-trimethoxyphenyl-3-(3-azidomethyl-isoxazolo(4,5-c) -1,2-dihydro-6-chloro-quinolin-2-on-1-yl)phenylacetamide ELI LILLY AND COMPANY 2003-12-30 US disclosed
US-20030232854-A1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 ELI LILLY AND COMPANY 2003-12-18 US disclosed
US-20030100576-A1 Methods and compounds for inhibiting mrp1 ELI LILLY AND COMPANY 2003-05-29 US disclosed
EP-1296953-A2 METHODS AND COMPOUNDS FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 2003-04-02 EP disclosed
EP-1250340-A1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 2002-10-23 EP disclosed
EP-1224189-A2 CONDENSED DIHYDROQUINOLINONE DERIVATIVES FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 2002-07-24 EP disclosed
WO-2002000624-A2 METHODS AND COMPOUNDS FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 2002-01-03 WO disclosed
WO-2001046199-A1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 2001-06-28 WO disclosed
WO-2001027116-A2 CONDENSED DIHYDROQUINOLINONE DERIVATIVES FOR INHIBITING MRP1 ELI LILLY AND COMPANY (US) 2001-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232854-A1 METHODS AND COMPOUNDS FOR INHIBITING MRP1 ABCC1, ABCB11, ABCB1 ALDH1A1 211/4885PKM 2532/4885MAPT 4315/4885
US-20040176405-A1 Methods and compounds for inhibitting MRP1 ABCC1, ABCB11, ABCB1 ALDH1A1 208/4885PKM 2387/4885MAPT 4012/4885
US-20040077675-A1 Compounds and methods for inhibiting MRP1 ABCC1, ABCB1, ABCB11 ALDH1A1 212/4885PKM 2081/4885MAPT 4342/4885
US-20030100576-A1 Methods and compounds for inhibiting mrp1 ABCC1, ABCB11, ABCB1 ALDH1A1 264/4885PKM 2445/4885MAPT 4262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.